Monoclonal antibody therapies against SARS-CoV-2.

Focosi, Daniele; McConnell, Scott; Casadevall, Arturo; Cappello, Emiliano; Valdiserra, Giulia; Tuccori, Marco

Focosi, Daniele; McConnell, Scott; Casadevall, Arturo; Cappello, Emiliano; Valdiserra, Giulia; Tuccori, Marco.

Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
McConnell S; Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD, USA.
Casadevall A; Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD, USA.
Cappello E; Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Valdiserra G; Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Tuccori M; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: marco.tuccori@gmail.com.

Lancet Infect Dis ; 22(11): e311-e326, 2022 11.

Artículo en Inglés | MEDLINE | ID: covidwho-2308470

ABSTRACT

ABSTRACT

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.

Asunto(s)

COVID-19; SARS-CoV-2; Humanos; Glicoproteína de la Espiga del Coronavirus; Pandemias; Anticuerpos Monoclonales/uso terapéutico; Anticuerpos Antivirales/uso terapéutico; Anticuerpos Neutralizantes

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio pronóstico Tópicos: Variantes Límite: Humanos Idioma: Inglés Revista: Lancet Infect Dis Asunto de la revista: Enfermedades Transmisibles Año: 2022 Tipo del documento: Artículo País de afiliación: S1473-3099(22)00311-5

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google